glp-1 receptor agonists in pediatric and adolescent obesity prescribing among teens with Neurobiological Mechanisms and Therapeutic Potential

Weight loss was more pronounced in patients with a BMI over 35, compared to those under 35

They believed it differed from pancreozymin, another small intestine hormone identified by Ivy in 1928 that was subsequently renamed cholecystokinin (CCK) (Kosaka, Lim)

Reduced side effects: Because the amylin component helps, patients may not need as high a dose of semaglutide, potentially lowering nausea

View at Publisher | View at Google Scholar Green BD et al

Maintains Healthy Blood Sugar Levels: Chromium picolinate helps stabilize blood sugar, preventing energy dips and unnecessary snacking

Still, insurance coverage and cost considerations mean both drugs remain relevant, and patient-centred conversations about therapy choice are critical. GLP-1s beyond weight loss as multi-system therapies Liver disease and metabolic steatohepatitis Non-alcoholic fatty liver disease (NAFLD) and the more severe metabolic dysfunction-associated steatohepatitis (MASH) have few effective pharmacologic treatments